Skip to content

Study on the Safety and Effectively of Optimized Antiviral Therapy and ePRO in Vulnerable People with AIDS

Study on the Safety and Effectively of Optimized Antiviral Therapy and ePRO in Vulnerable People with AIDS

Status
Recruiting
Phases
Phase 4
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500097627
Enrollment
Unknown
Registered
2025-02-22
Start date
2025-02-28
Completion date
Unknown
Last updated
2025-03-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

AIDS

Interventions

One:HIV patients who receive national free drug treatment
Two:HIV patients who receive medical insurance drug treatment

Sponsors

The First Affiliated Hospital, Zhejiang University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: (1) Patients aged between 18 and 65 years old. (2) Confirmed to be infected with HIV through the initial screening test and the Western Blot (WB) confirmation test. (3) The viral load detected is lower than the minimum detectable value. (4) The number of CD4+ T cells is greater than 200 cells/mm³. (5) Voluntarily sign the patient informed consent form and be able to ensure acceptance of regular follow-up, specimen collection, and reporting of relevant adverse reactions to treatment. (6) Meeting one of the following conditions: patients aged over 50 years old; late diagnosis; patients with multiple underlying diseases; patients with highly suppressed immunity, such as the CD4+ T lymphocyte count < 50/µL; incomplete immune reconstitution after antiretroviral therapy (ART).

Exclusion criteria

Exclusion criteria: (1) Pregnant or lactating women, or those who plan to become pregnant during the study observation period. (2) Those with poor treatment compliance. (3) Patients with severe underlying diseases of the heart, brain, liver, kidney, etc., with a neutrophil count < 1000/mm³, a platelet count < 75,000/mm³, patients who are allergic to the study drugs or have other treatment contraindications.

Design outcomes

Primary

MeasureTime frame
Plasma human immunodeficiency viral load;CD4+ T cell count;cytokines;

Countries

China

Contacts

Public ContactBiao Zhu

The First Affiliated Hospital, Zhejiang University School of Medicine

zhubiao1207@zju.edu.cn+86 571 8723 6416

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026